Rheumatoid Arthritis News

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, discussed a session on the new ACR recommendations for managing patients with rheumatoid arthritis.

Among patients with rheumatoid arthritis, 30 days of glucocorticoid use in 6 months is associated with 15% increased odds of major adverse cardiac events in the next 6 months, according to data presented at ACR Convergence 2021.

Patients with rheumatoid arthritis, gout, polydermatomyositis, vasculitis and those with multiple rheumatic diseases were at greatest risk for breakthrough COVID-19 infection, despite full or partial vaccination vs. those without rheumatic disease.

Tofacitinib is associated with a numerically higher incidence of major adverse cardiac events, versus TNF inhibitors, in patients with rheumatoid arthritis at an increased cardiac risk, according to data presented at ACR Convergence 2021.

Unemployment and poverty can be significant drivers of poor outcomes in conditions like rheumatoid arthritis and systemic lupus erythematosus, according to a keynote lecture at ACR Convergence 2021.

Patients with rheumatoid arthritis who fail their first JAK inhibitor can achieve success with either “cycling” to another JAK inhibitor or switching to a biologic disease-modifying antirheumatic drug, according to data presented at ACR Convergence 2021.

Data presented at ACR Convergence 2021 support the use of life-saving lung transplantation among qualified patients with systemic autoimmune diseases.

Among fully vaccinated individuals with rheumatic diseases, breakthrough COVID-19 infections occurred most commonly in patients treated with B cell depleting agents or mycophenolate, according to data presented at ACR Convergence 2021.

In an extension of the REDO trial, most patients with rheumatoid arthritis on ultra-low-dose rituximab — either 200 or 500 mg — maintained low disease activity for up to 4 years, according to data presented at ACR Convergence 2021.

Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.